-
-
-
-
-
-
-
Indaptus Therapeutics (INDP) Files for 2.16M Share Offering by Selling Stockholders
-
-
-
-
-
-
-
Indaptus Therapeutics (INDP) Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
-
-
-
-
-
-
-
Indaptus Therapeutics, Inc. (INDP) Tops Q3 EPS by 16c
-
-
-
-
-
456,324 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

